Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival
K. Van Besien, A. Rodriguez, S. Tomany, A. Younes, M. Donato, A. Sarris, S. Giralt, R. Mehra, B. Andersson, J. Gajewski, R. Champlin, F. Cabanillas
Research output: Contribution to journal › Article › peer-review
Dive into the research topics of 'Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival'. Together they form a unique fingerprint.